Crossmark

Household costs in the United States for accommodating functional impairments associated with Duchenne muscular dystrophy: results from a caregiver survey

Crossref DOI link: https://doi.org/10.1186/s13023-025-03794-1

Published Online: 2025-06-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Innis, Bryan https://orcid.org/0009-0008-7274-3942
Jarvis, John

Renteria, Taylor

Audhya, Ivana
Funding

Funding for this research was provided by:

Sarepta Therapeutics, Inc. (Sarepta Therapeutics, Inc.)
License Information

Text and Data Mining valid from 2025-06-12

Version of Record valid from 2025-06-12
More Information

Article History

Received: 20 December 2024

Accepted: 13 May 2025

First Online: 12 June 2025

Declarations

:

: This non-interventional study was exempted from institutional review by WCG Institutional Review Board. Informed consent was obtained from all caregivers prior to initiation of the survey.

: Not applicable.

: BI and IA are employees of Sarepta Therapeutics, Inc., and may hold stock or stock options. JJ and TR are employed by Medicus Economics, which received consulting fees from Sarepta Therapeutics, Inc.

Document is current

Any future updates will be listed below